Please login to the form below
Cx601
This page shows the latest Cx601 news and features for those working in and with pharma, biotech and healthcare.
Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy
Alofisel - previously Cx601 - is approved to treat complex perianal fistulas in adult patients with nonactive or mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at
Latest news
-
Takeda offers €520m for stem cell firm TiGenix
CX601 has been classed as an orphan treatment for treating people who don’t respond to drug therapy. ... offers the best capabilities and resources to ensure access to Cx601 to patients worldwide.”.
-
CHMP backs Europe’s first allogeneic stem cell therapy
Takeda paid 25m upfront for rights to Cx601 for this indication outside the US, pledging another 355m in milestone payments, including 15m on approval by the EMA. ... TiGenix still owns the US rights to Cx601, considered a larger market opportunity for
-
TiGenix’s Crohn's fistulas treatment wins orphan drug status
The drug - currently known as Cx601 - could potentially treat ‘complex’ perianal fistulas in patients with Crohn’s disease who have had an inadequate response to at least one conventional or biologic ... Meanwhile, TiGenix and partner Takeda has
-
TiGenix cell therapy for Crohn's fistulas shows long-term benefit
In ADMIRE-CD, 56% of patients treated with Cx601 and usual supportive care went into remission, compared to 39% of patients who received placebo plus standard care. ... Existing therapies are limited and associated with complications and a high failure
More from news
Approximately 3 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
authorisation for Cx601, so it was probably a good time for Takeda to make a move. ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead asset, allogeneic expanded adipose-derived stem cells (eASC) locally administered for treatment of
-
Deal Watch July 2016
Other deals where the licensee has committed real upfront money include Takeda's $28m upfront payment for ex-US rights to TiGenix's Cx601, a suspension of allogeneic adipose-derived stem ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
TiGenix appoints Dr Marie Paule Richard
In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Medical Editor
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- New study identifies drugs that are safe to use in COVID-19 treatment
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- Trial combining British and Russian COVID-19 vaccines could begin in February
- Merck ends its COVID-19 vaccine programme after disappointing early trial results
- AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU
- Pfizer/BioNTech reach vaccine supply agreement with COVAX
- BMS gains FDA approval for second Opdivo combo in kidney cancer
- An EU emergency health fund to limit the impact of future crises
- Mistrust in medical research: a patient perspective
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- An EU emergency health fund to limit the impact of future crises
- Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
Quick links
Infographics
